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ABSTRACT: The cellular response to hypoxia is orchestrated
by HIF-1, a heterodimeric transcription factor composed of an
α and a β subunit that enables cell survival under low oxygen
conditions by altering the transcription of over 300 genes.
There is signiﬁcant evidence that inhibition of HIF-1 would be
beneﬁcial for cancer therapy. We recently reported a cyclic
hexapeptide that inhibits the HIF-1α/HIF-1β protein−protein
interaction in vitro and prevents HIF-1-mediated hypoxia-
response signaling in cells. This cyclic peptide was identiﬁed
from a library of 3.2 × 106 members generated using
SICLOPPS split-intein mediated protein splicing. With a view to demonstrating the potential for encoding the production of
a therapeutic agent in response to a disease marker, we have engineered human cells with an additional chromosomal control
circuit that conditionally encodes the production of our cyclic peptide HIF-1 inhibitor. We demonstrate the conditional
production of our HIF-1 inhibitor in response to hypoxia, and its inhibitory eﬀect on HIF-1 dimerization and downstream
hypoxia-response signaling. These engineered cells are used to illustrate the synthetic lethality of inhibiting HIF-1 dimerization
and glycolysis in hypoxic cells. Our approach not only eliminates the need for the chemical synthesis and targeted delivery of our
HIF-1 inhibitor to cells, it also demonstrates the wider possibility that the production machinery of other bioactive compounds
may be incorporated onto the chromosome of human cells. This work demonstrates the potential of sentinel circuits that
produce molecular modulators of cellular pathways in response to environmental or cellular disease stimuli.
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■ INTRODUCTION
Transcription factors are master regulators of cellular fate and
function that orchestrate a coordinated response to a variety
physiological stimuli. Exogenous modulation of transcription
factor activity therefore holds much therapeutic potential, and is
a critical tool for deciphering complex cellular networks. The
absolute requirement of assembly for function means that
protein−protein interaction (PPI) inhibition is the optimal
strategy for intervention, but transcription factors are
considered to be one of the most chemically intractable targets
in drug discovery.1 More generally, the challenge of identifying
PPI inhibitors means that the majority of tools employed for
studying these complexes are nucleic acid-based (e.g., siRNA, or
CRISPR) and function to eliminate the targeted protein from
the cell. Despite their widespread use, these methods have
several drawbacks for studying PPIs; removal of a protein from
a system eliminates all of its known and unknown interactions
and functions. Thus, an observed phenotype may not
necessarily be attributed to a given PPI. In cases where
validated PPI inhibitors are available, the need for chemical
synthesis and intracellular delivery of such compounds places
limitations on their adaptation and use. We sought an
alternative approach by introducing the components necessary
to synthesize a PPI inhibitor onto the genome of a human cell
line. Under this scenario, the intracellular production of a non-
native molecule is selectively induced by one or more disease
speciﬁc signals via expression of the machinery needed for its
production. This approach would have the advantage that it
eliminates the need for chemical synthesis and intracellular
delivery of the therapeutic agent. To demonstrate the viability
of the proposed approach, we turned to our recently reported
cyclic peptide inhibitor of hypoxia inducible factor 1 (HIF-1)
heterodimerization.2
HIF-1 is a heterodimeric transcription factor that drives the
cellular response to hypoxia,3,4 by altering the transcription of
over 300 genes,5 enabling cell survival and growth in a low
oxygen microenvironment. HIF-1 is composed of an oxygen-
regulated α-subunit (HIF-1α) and a constitutively expressed β-
subunit (HIF-1β). HIF-1α is marked for degradation by prolyl
hydroxylases that use oxygen as a substrate.6,7 Reduced oxygen
levels lead to the stabilization and nuclear translocation of HIF-
1α, where it binds HIF-1β to form the active HIF-1
transcription factor. HIF-1α mounts an immediate response
to reductions of intracellular oxygen,8 while two closely related
isoforms, HIF-2α (also known as EPAS1) and HIF-3α, are
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thought to regulate the response to prolonged hypoxia.9 The
intricate interplay between HIF-α isoforms in cancer is complex
and yet to be fully deciphered, but the role of HIF-1 activity in
angiogenesis, tumor growth and metastasis is well estab-
lished.10,11 Tumours grow rapidly, outstripping the capacity of
the local vasculature, which results in a hypoxic microenviron-
ment; HIF-1α is overexpressed in many cancers,12 and
oncogene activation and loss of tumor suppressor function is
shown to be associated with HIF-1.13
We recently reported an inhibitor of the HIF-1α/HIF-1β
PPI;2 this molecule (cyclo-CLLFVY, named P1) was identiﬁed
from a genetically encoded library of 3.2 million cyclic
hexapeptides generated using split-intein circular ligation of
peptides and proteins (SICLOPPS).14,15 P1 selectively binds to
the PASB domain of HIF-1α with a Kd of 124 nM, disrupts the
HIF-1α/HIF-1β PPI in vitro and in cells, and inhibits HIF-1
signaling in hypoxic cells.2 P1 is isoform-speciﬁc and does not
bind to, or aﬀect the function of the closely related HIF-2
isoform in vitro or in cells.2 SICLOPPS generates cyclic
peptides via Synechocystis sp PCC6803 (Ssp) DnaE split
inteins;16 the SICLOPPS protein is composed of rearranged
N-terminal and C-terminal split inteins ﬂanking a peptide
extein sequence in the form of IC-extein-IN. The N- and C-
terminal split inteins combine to form an active intein that
splices to cyclize the extein (Figure S1A). By altering the
sequence of the SICLOPPS extein at the DNA level, a variety
of cyclic peptides and proteins, including randomized cyclic
peptide libraries, may be produced by this approach.17
Given our goal of incorporating the machinery required for
the generation of a molecular PPI modulator into cells, and the
signiﬁcance of HIF-1 in tumor survival and growth, we set out
probe the possibility of engineering the conditional production
of P1 (via the corresponding SICLOPPS inteins) onto the
chromosome of human HEK-293 cells, and to assess the eﬀect
of genetically encoded P1 on HIF-1-mediated hypoxia response
in these cells.
■ RESULTS
Expression and Processing of SICLOPPS Constructs in
HEK-293 Cells.We began by constructing a cell line capable of
conditional P1 production and assessing the ability of the
SICLOPPS construct to correctly function in human cells. To
achieve inducible expression of the SICLOPPS construct
encoding our HIF-1 inhibitor, we used a cassette containing a
CMV promoter, followed by two copies of the tetracycline
operator (tetO), enabling regulation of transcription with
doxycycline (dox), followed by the gene for SICLOPPS (Figure
1A). Engineered Nostoc punctiforme DnaE (Npu) inteins that
splice signiﬁcantly faster than the Ssp inteins typically used in
SICLOPPS18−20 were utilized for the production of P1, with
CLLFVY as the extein to be cyclized. We used ﬂippase-ﬂippase
recognition target (Flp-FRT) recombination21 to stably
integrate this cassette onto the chromosome of human HEK-
293 cells (T-REx-293) to give T-REx-P1 cells. We ﬁrst sought
to demonstrate the production of functional P1 from the
chromosome of human cells. Intein production was probed by
immunoblotting with an antibody against the chitin-binding
domain (CBD) present on the C-terminus of the N-terminal
intein; we only observed the CBD band in the integrated cells,
and only when cultured with dox (Figure S2A). The change in
transcription of the chromosomal SICLOPPS construct in
response to dox was quantiﬁed by RT-qPCR as ∼37-fold in
both normoxia and hypoxia (Figure 1B), which was also
reﬂected at the protein level (Figure 1C). A time course
measuring intein protein production over 24 h in hypoxic cells
illustrated the steady buildup of SICLOPPS inteins (Figure
1D). The splicing eﬃciency of the SICLOPPS protein
encoding P1 was measured by immunoblot analysis for the
CBD. We only observed a single band at ∼18 kDa
corresponding to the spliced N-intein, suggesting full splicing
of the SICLOPPS protein (Figure S2B). We next sought to
directly detect the presence of P1 in T-REx-P1 cells. A synthetic
sample of P1 was prepared as a standard, and a peak with
identical retention time as this sample was observed in the
lysate of T-REx-P1 cells treated with dox (Figure 1E). Mass
spectrometric analysis of this fraction from the cell lysate
revealed peaks corresponding to the mass of P1 (Figure 1F)
and the same as observed for the synthetic standard (Figure
S3). This data demonstrates that the Npu SICLOPPS inteins
incorporated into the chromosome of human HEK-293 cells
are selectively produced in the presence of dox, splicing post
translation to give detectable levels of P1 in the engineered
human cell line.
Genetically Encoded P1 Inhibits HIF-1 Activity. With
the engineered cell line in hands and having demonstrated the
conditional production of P1, the functionality of the
genetically encoded cyclic peptide HIF-1 inhibitor was next
probed. T-REx-P1 cells were transfected with a HIF-dependent
luciferase reporter plasmid, where activation of HIF results in
increased luciferase expression.22 As expected, there was no
change in the luciferase signal with dox in normoxia, while an
∼8-fold increase in luciferase activity was observed in hypoxic
T-REx-P1 cells without dox (Figure 1G). Induction of P1
production with dox in these cells resulted in a 50% decrease in
luciferase activity (Figure 1G), suggesting that chromosomally
encoded P1 inhibits HIF-1 function. To demonstrate that our
observations are due to P1 and not the SICLOPPS inteins, we
generated a negative control cell line (T-REx-Scramble) that
chromosomally encoded cyclo-CFVLYL (a scrambled variant of
P1) as the extein of Npu SICLOPPS inteins. Splicing and
conditional production of this scrambled peptide was
demonstrated by immunoblotting (Figure S4). The above
luciferase assay was repeated in this cell line, and a ∼7-fold
increase in luciferase activity was observed upon induction of
hypoxia without dox. There was, however, no change in
luciferase activity when these cells were incubated with dox in
hypoxia (Figure 1G), indicating that the scrambled peptide, or
the SICLOPPS inteins do not aﬀect HIF-1 dimerization. To
validate that the eﬀect from P1 was on HIF-1 rather than on
luciferase, we used a control SV40-luciferase plasmid, and did
not see any signiﬁcant change in luciferase signal upon
induction of P1 in T-REx-P1 cells with dox (Figure S5).
The eﬀect of chromosomally produced P1 on HIF-1 activity
was further assessed via its target genes vascular endothelial
growth factor (VEGF) and carbonic anhydrase IX (CAIX).
Chromosomally produced P1 reduced VEGF transcription by
∼30% (Figure S6A) and CAIX transcription by ∼45% (Figure
S6B), with no eﬀect of the scrambled peptide observed on
either gene (Figure S6). Together, the above data demonstrates
that chromosomally encoded P1 is functional, and able to
inhibit HIF-1 signaling in hypoxia as expected from our
previous studies with the synthetic, tat-tagged variant of the
compound.
Engineering Physiological Control of Peptide Ex-
pression. We next sought to engineer an additional layer of
control into the above system by limiting the dox-dependent
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production of P1 to hypoxic cells. The motivation for
constructing this dual-control system was our long-term goal
of generating an in vivo model that contains such a circuit on its
chromosome. Such a system would not only allow expression of
the HIF-1 inhibitors in hypoxic tissues (as an HRE-only
promoter would), but also allow temporal control over
initiation of P1 production via addition of dox. Thus, the
eﬀect of HIF-1 inhibition at various stages of the tumor
development may be assessed. A hybrid promoter was designed
and constructed; three copies of the HRE from the inducible
nitric synthase promoter22 were placed upstream of two copies
of TetO, resulting in a dual physiological and chemically
controlled conditional promoter that would only function in
hypoxia and with dox (Figure 2A). This cassette was
incorporated onto the chromosome of HEK-293 cells by Flp-
FRT recombination (as above) to give T-REx-HRE cells.
Analysis of SICLOPPS cassette transcription by RT-qPCR
showed ∼9-fold upregulated transcription in hypoxic cells that
were incubated with dox (Figure 2B). Immunoblot analysis
showed the presence of SICLOPPS protein only in cells
cultured in hypoxia and with dox (Figure 2C), further
illustrating that the dual conditional promoter was functioning
as designed. The quantity of SICLOPPS protein was next
compared with T-REx-P1 cells. Interestingly, we observed
higher levels of inteins in the CMV-promoted cell line than the
HRE-promoted cells incubated in hypoxia and with dox (Figure
S7). Analysis of these bands by densitometry indicated that
there was ∼7-fold more SICLOPPS intein in T-REx-P1 cells
than in T-REx-HRE cells after 24 h. There are two reasons for
this diﬀerence; ﬁrst, the transgene expression rate from the
HRE promoter is known to be lower than that from a CMV
promoter,23,24 and second, the spliced product of the promoted
protein (P1) is an inhibitor of HIF-1 dimerization. Therefore,
as P1 builds up, it will also inhibit the transcription factor
promoting its own production. To further assess the eﬀect of
this feedback loop on P1 production, a time course analysis of
intein production was conducted. We observed the steady
buildup of SICLOPPS mRNA (Figure 2D) and protein (Figure
2E) in hypoxic T-REx-HRE cells over 24 h, with a noticeable
increase in both after 8 h in hypoxia.
The eﬀect of P1 on the interaction of HIF-1α and HIF-1β in
hypoxic T-REx-HRE cells was next directly probed using an in
situ proximity ligation assay (PLA).2,25 A PLA signal was
observed in hypoxic T-REx-HRE cells incubated without dox
Figure 1. Production of a functional cyclic peptide HIF-1 inhibitor from the chromosome of human HEK-293 cells. (A) The chromosomally
integrated cassette enables the conditional expression of the SICLOPPS gene, which encodes the Npu inteins with CLLFVY as the extein. Splicing of
these inteins gives P1. (B) RT-qPCR of intein expression in T-REx-P1 cells incubated in normoxia or hypoxia (24 h). (C) Immunoblot of T-REx-
293 and T-REx-P1 cells treated as in B. (D) Immunoblot of T-REx-HRE cells incubated with dox in hypoxia for 0−24 h. (E) P1 produced in T-REx-
P1 cells has the identical HPLC retention time as the synthetic standard. (F) The mass spectrum (ESI+) of fraction shown in F from T-REx-P1 cell
lysate shows the presence of P1. (G) Fireﬂy luciferase activity in T-REx-P1 and T-REx-Scram cells transfected with TK-HRE-luciferase and incubated
for under normoxia or hypoxia (16 h). Data are means (n = 3) ± SEM, **p < 0.01.
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(Figure 2F, left-hand panel), corresponding to the hypoxia-
induced stabilization of HIF-1α and subsequent dimerization of
HIF-1α and HIF-1β. The PLA signal was not observed in these
cells when incubated with dox (Figure 2F, right-hand panel),
nor in normoxic cells with or without dox (Figure S8). This
data demonstrates the disruption of HIF-1 dimerization by
genetically encoded P1 in cells.
The downstream eﬀect of disrupting HIF-1 dimerization
with chromosomally encoded P1 was elucidated via analysis of
the transcription of HIF-1 target genes VEGF and CAIX. The
expression of both genes was measured by RT-qPCR in cells
incubated in hypoxia for 24 h with or without dox. Induction of
P1 with dox resulted in a ∼40% reduction in VEGF mRNA
(Figure 2G) and a ∼50% reduction in CAIX mRNA in hypoxic
T-REx-HRE cells (Figure 2H). It should be noted that although
lower amounts of the SICLOPPS protein are produced in the
T-REx-HRE cells than in T-REx-P1 cells, the extent of the
eﬀect of P1 on these HIF-1 reporter genes was similar in both
cell lines, indicating that P1 concentration is not a limiting
factor in the observed inhibition of HIF-1 signaling.
Endogenous P1 Expression Alters Transcriptional
Response to Hypoxia. We broadened our analysis of the
eﬀect of P1 on HIF-1 signaling by using a focused microarray
assessing expression of 43 hypoxia-associated genes (Table S1)
in T-REx-HRE cells cultured in normoxia, hypoxia, and hypoxia
with dox. The data showed altered expression of these genes in
T-REx-HRE cells that were incubated in hypoxia with dox
(Figure 3A), illustrating the reprogramming of hypoxia
response by P1 in these cells. We have previously demonstrated
(in vitro and in cells) that cyclo-CLLFVY is a speciﬁc inhibitor
of HIF-1 dimerization that does not aﬀect the interaction of
HIF-2α and HIF-1β.2 We therefore aimed to illustrate the
Figure 2. Conditional production of P1 in human cells. (A) The hybrid HRE/TetO promoter requires dual input signals of HIF-1 and dox in an
AND process for expression of the SICLOPPS construct. Intein splicing produces P1, which inhibits HIF-1 dimerization. (B) RT-qPCR analysis of
intein expression in T-REx-HRE cells incubated for 24 h in normoxia or hypoxia, with or without 1 μg/mL dox. (C) Immunoblot of T-REx-HRE
cells treated as in panel B. (D) RT-qPCR analysis of SICLOPPS mRNA levels in T-REx-HRE cells incubated in hypoxia for 0−24 h and treated with
1 μg/mL dox. (E) Immunoblot for production of SICLOPPS protein over time. T-REx-HRE cells treated as in panel D. (F) PLA of T-REx-HRE
cells treated with vehicle (left panel) or dox (right panel) and incubated in hypoxia for 24 h. (G and H) RT-qPCR analysis of (G) VEGF and (H)
CAIX expression in T-REx-HRE cells incubated in hypoxia for 24 h with or without 1 μg/mL dox. Data are means (n = 3) ± SEM, **p < 0.01,
****p < 0.0001.
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potential of using genetically encoded P1 to separate the eﬀect
of HIF-1 inhibition on hypoxia signaling from that of the
closely related transcription factor HIF-2. Our control experi-
ments showed that treatment of T-REx-HRE cells with dox had
no eﬀect on HIF-2α mRNA levels (Figure S9A), and that
siRNA knockdown of HIF-2α did not signiﬁcantly aﬀect the
expression of HIF-1α mRNA or protein (Figure S9B and S9C)
or SICLOPPS protein (Figure S9D).
The isoform-speciﬁcity of a number of HIF-target genes was
next assessed using the above approach. While there was no
eﬀect on HIF-1α mRNA from either HIF-1 or HIF-2 (Figure
3B), HIF-3α expression seemed to be primarily under the
control of HIF-2 (Figure 3C). We next assessed the role of HIF
isoforms on genes involved in angiogenesis (ANGPLT4 and
VEGF) and erythropoiesis (EPO). Following dox treatment,
expression of EPO was decreased to normoxic levels, whereas
HIF-2α siRNA treatment caused no signiﬁcant change,
indicating EPO is a HIF-1 speciﬁc target (Figure 3D). In
contrast, although inhibition of HIF-1 signiﬁcantly reduced the
expression of ANGPLT4 (Figure 3E) and VEGF (Figure S9E),
a combination of both dox and HIF-2α siRNA treatments was
required to reduce gene expression to normoxic levels. This
data suggests that expression of ANGPLT4 and VEGF is
transactivated by both HIF-1 and HIF-2. Together, the
inhibitory eﬀect of P1 expression on genes involved in the
promotion of angiogenesis and erythropoiesis supports
previous assertions for the potential of targeting HIF-1
dimerization as a therapeutic strategy to prevent tumor
vascularisation.
Inhibition of HIF-1 dimerization and HIF-2α siRNA
treatment also diﬀerentially impacted upstream eﬀectors of
oxygen-dependent regulation of HIF-1. Induction of P1
expression resulted in a decrease in PHD2 and PHD3 mRNA
whereas HIF-2α siRNA had no signiﬁcant eﬀect (Figure 3F and
Figure 3. Expression of genetically encoded P1 alters the transcriptional proﬁle of hypoxic HEK-293 cells. (A) Heat map of relative gene expression
in T-REx-HRE cells transfected incubated in normoxia, or 24 h in hypoxia with or without 1 μg/mL dox. Details of genes are given in Table S1. (B−
I) RT-qPCR analysis of T-REx-HRE cells incubated in normoxia, or 24 h in hypoxia with or without HIF-2α siRNA, and with 1 μg/mL dox with or
without HIF-2α siRNA. Fold change in gene expression is shown relative to normoxic expression (dotted line). Data are means (n = 3) ± SEM, **p
< 0.01, ***p < 0.001, ****p < 0.0001.
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3G). These observations are in line with the theory that HIF-1
mediates the acute response to hypoxia whereas HIF-2 is the
prominent driver of adaptation to prolonged periods of hypoxic
conditions.26,27 Another gene primarily controlled by HIF-1
was CAIX, with no signiﬁcant eﬀect from HIF-2α siRNA alone
(Figure S9F). This data was in agreement with reports of CAIX
as a HIF-1 speciﬁc target.28 Interestingly, although the stress
response gene DDIT4 was upregulated in hypoxia, and
inhibition of HIF-1 and HIF-2 signiﬁcantly reduced this
induction, neither treatment was suﬃcient to reduce DDIT4
expression to normoxic levels (Figure 3H). DDIT4 is also
induced in response to endoplasmic reticulum stress and DNA
damage related to the regulation of reactive oxygen species,29,30
which may be a result of hypoxic exposure, particularly when
HIF response pathways are disrupted.30 Another gene of note
was NOTCH-1, whose expression was halved in hypoxic cells
treated with dox, but doubled in hypoxic cells treated with HIF-
2α siRNA (Figure 3I), illustrating the opposing regulatory roles
of HIF-1 and HIF-2 on this gene. The above data not only
demonstrates reprogramming of hypoxia response in our
engineered human cell line, but also illustrates the potential
utility of using genetically encoded P1, a HIF-1 speciﬁc
inhibitor, to decipher the role of HIF isoforms in hypoxia
signaling in a variety of cell lines.
Inhibition of HIF-1 Dimerization Confers Synthetic
Lethality to Glycolysis Inhibitor. The eﬀect on cell viability
from the disruption of hypoxia-response signaling via inhibition
of the HIF-1α/HIF-1β PPI by P1 was next probed. The
viability of T-REx-HRE cells cultured in normoxia or hypoxia,
with or without dox was assessed over 72 h using 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT).
No diﬀerence was observed in the viability of cells cultured with
dox versus those that were not (Figure 4A and Figure S10),
indicating that inhibition of the HIF-1α/HIF-1β PPI in hypoxic
HEK-293 cells does not aﬀect viability. Nonetheless, previous
studies have shown that knockdown of HIF-1α by siRNA
sensitizes cells to the glycolysis inhibitor 2-deoxyglucose
(2DG), leading to cytotoxicity.31 We questioned whether
inhibition of HIF-1α/HIF-1β PPI with P1 would render HEK-
293 cells susceptible to 2DG. This was initially assessed using
MTT assays as above. We observed a 37% reduction in viability
after 72 h in hypoxic T-REx-HRE cells incubated with dox
(Figure 4B). This observation was further probed with a triplex
assay that uses protease biomarkers to assess viability,
cytotoxicity and apoptosis.32 We observed a 45% decrease in
the ratio of viable to cytotoxic T-REx-HRE cells after 72 h
(Figure 4C), in line with our observations from the MTT assay.
Interestingly, no signiﬁcant increase in caspase-3/7 activity was
observed in these cells (Figure 4D), suggesting that the
observed synthetic lethality of 2DG combined with P1 is not
driven by apoptosis.33
■ DISCUSSION
The conditional production of P1, an inhibitor of the HIF-1α/
HIF-1β PPI, has been encoded onto the chromosome of a
human cell line, and demonstrated to be a viable approach for
the inhibition of HIF-1 signaling. Two versions of this sentinel
circuit are reported, one that initiates P1 production in
response to a chemical trigger (doxycycline), and a second
that requires an environmental signal (hypoxia) in addition to
doxycycline. In addition, the synthetic lethality of HIF-1
dimerization inhibition (by P1) and inhibition of glycolysis
(with 2DG) is demonstrated. There is a growing body of
evidence that inhibition of HIF-1, or redirection of cellular
pathways away from HIF-1 controlled mechanisms, may
improve the anticancer eﬀects of current chemotherapeutic
agents.34−37 Using the T-REx-HRE cell line reported here, a
variety of chemotherapeutic agents may be screened for
synthetic lethality, or increased potency when combined with
HIF-1 inhibition.38,39
Figure 4. Assessing the eﬀect of HIF-1 inhibition on T-REx-HRE cell viability. (A) Cells were incubated in hypoxia for up to 72 h with or without 1
μg/mL dox. Cell viability was assessed with an MTT assay. (B) Cells were treated as in panel A with or without the addition of 3 mg/mL 2DG to the
culture media. (C) Cells were treated as in panel B and incubated in hypoxia for 72 h. The ratio of cell viability to cytotoxicity was determined using
a triplex reporter assay. (D) Cells were treated as in panel C and apoptotic cell death was assessed via a caspase 3/7 activity assay. Data are means (n
= 3) ± SEM, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
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This system has the potential to address several key
questions about HIF-1 and its necessity for the survival and
growth of tumors. Since its discovery, a large body of evidence
has suggested that the HIF-1 transcription factor plays a
signiﬁcant and critical role in cancers, enabling survival and
adaptation in the hypoxic tumor microenvironment. However,
recent studies have indicated that HIF-1α also functions in the
cell as a monomer.40−42 Approaches that enable disruption of
the HIF-1 transcription factor, without reducing the cellular
level of HIF-1α have the potential to help decipher the role of
HIF-1 in cancer. The sentinel circuit reported above may, for
example, be incorporated onto the genome of a variety of
cancer cell lines that are used in xenograft models. P1
production may be initiated at various points during the
tumor lifecycle, either globally or only within the hypoxic
regions of the tumor, illustrating the signiﬁcance (or not) of
HIF-1 as a target for cancer therapy. Another possibility is the
generation of in vivo models that contain the sentinel P1-
encoding circuit on their chromosome, enabling the eﬀect of
long-term HIF-1 inhibition on tumor formation and main-
tenance to be studied; the dual control promoter limits P1
production to hypoxic cells and allows temporal control over
P1 production, enabling the study of HIF-1 inhibition at
various stages of the tumor lifecycle.
The concept of encoding the conditional production of a
non-native small molecule from the genome of engineered
human cells has applications beyond the HIF-1α/HIF-1β
inhibitor described here. There are a multitude of natural
products used as therapeutics that may be hard-coded onto
cells via their biosynthetic machinery, and produced as
required. The use of sentinel circuits to induce apoptosis in
cells in response to speciﬁc DNA sequences,43 or encoding an
environment-coupled kill-switch in bacteria44 attests to the
possibilities. Other recent examples include the introduction of
new biological components into cells for therapeutic
purposes.45−50 As the ﬁeld of synthetic biology advances,
such examples will grow in number and complexity.
■ METHODS
Cell Culture. All cell culture reagents were purchased from
Life Technologies unless otherwise stated. All cells were
cultured at 37 °C in a humidiﬁed 5% CO2 atmosphere. T-REx-
293 cells were maintained in DMEM containing 10% fetal
bovine serum (FBS), 100 μg/mL zeocin and 15 μg/mL
blasticidin and integrated T-REx cell lines were cultured in
DMEM containing 10% FBS, 100 μg/mL hygromycin B and 15
μg/mL blasticidin. Unless otherwise stated, T-REx cells were
dosed with 1 μg/mL doxycycline (dox) to induce expression of
integrated constructs. Hypoxia treatment was achieved in a
Don Whitley Scientiﬁc H35 Hypoxystation with a humidiﬁed
atmosphere containing 1% O2 and 5% CO2. Transfection of
plasmids was carried out using FuGENE HD (Promega)
according to the manufacturer’s instructions and experiments
were carried out 24 h after transfection.
Transfection and Selection of Stable Clones. Stable
mammalian expression cell lines were generated by Flp
recombinase-mediated integration. Flp-In T-REx-293 (T-REx-
293) cells and plasmid vectors pcDNA5/FRT/TO and pOG44
(kind gift of Dr. Noel Wortham) are available commercially
from Life Technologies. pOG44 and pcDNA5/FRT vectors
were transfected, at a ratio of 9:1, into T-REx-293 cells with
Fugene HD for the generation of stable cell lines. Polycolonal
selection was carried out with 200 μg/mL hygromycin in high
dilution culture. Integration was conﬁrmed by western
immunoblotting.
Quantitative PCR. Total RNA was extracted from cells
using ReliaPrep RNA Cell Miniprep System (Promega) and
quantiﬁed using a Nanodrop ND-1000 spectrophotometer.
Complementary cDNA was synthesized in a 20 μL reaction
using 1 μg of total RNA with GoScript Reverse Transcriptase
(Promega) according to the manufacturer’s instructions.
Quantitative real-time PCR (RT-qPCR) was performed using
Universal Taqman PCR master mix (Applied Biosystems) and
the TaqMan gene expression assays of interest (Applied
Biosystems) on a CFX-connect 96 Real-Time PCR system
(Bio-Rad). Expression assays used in this study were: 18S
(Hs99999901_s1), ActB (Hs99999903_m1), VEGF
(Hs00900055_m1), CAIX (Hs00154208_m1), HIF-1α
(Hs00153153_m1) and EPAS1 (Hs01026149_m1). Expres-
sion values were expressed as ΔΔCT normalized to expression
of 18S and β-Actin and normoxic gene expression. Hypoxia
focused microarray was conducted using TaqMan Array
Human Hypoxia plates (Applied Biosystems). Expression
values were expressed as ΔΔCT normalized to expression of
18S and normoxic gene expression.
Western Immunoblotting. For visualization of expression
of CBD tagged inteins, cells were lysed in intein extraction
buﬀer (20 mM Tris.HCl, 1 mM TCEP, 0.5 mM NaCl, pH 7.8)
on ice for 15 min. For visualization of HIF-1α protein, cells
were lysed by incubation on ice with radioimmunoprecipitation
assay buﬀer (50 mM Tris (pH 7.4), 150 μM NaCl, 1 mM
EDTA, 1% v/v Triton X-100), and 1× protease inhibitor
cocktail (Sigma) for 20 min.
Cell lysates were sonicated in an ice water bath then
centrifuged at 10 000 rpm for 20 min at 4 °C, and the protein
concentration in the supernatant quantiﬁed by Bradford assay.
Proteins were separated on an SDS-PAGE gels (15% for CBD,
10% for HIF-1α), transferred to PVDF membranes (Invi-
trogen) and subjected to immunoblot analysis. Mouse
monoclonal anti-CBD (E8034S, 1:250, New England Biolabs)
anti-HIF-1α (610958, 1:250 BD Biosciences) were diluted in
PBS containing 5% nonfat powdered milk and 0.1% Tween-20
and incubated with the membrane overnight at 4 °C overnight.
Horseradish peroxidase conjugated antimouse antibody was
used as the secondary antibody, and monoclonal anti-βactin-
peroxidase antibody (A3854, 1:100 000, Sigma) served as a
loading control. Bound immunocomplexes were detected using
ECL prime Western blot detection reagent (RON2232, GE
Healthcare) and analyzed using a ChemiDoc Imaging System
(Bio-Rad) and Image Lab 4.0 software (Bio-Rad).
Detection of Peptide in Cell Lysates by HPLC and MS.
T-REx-P1 cells were scraped in ice cold PBS and the cell pellet
froze in N2 (l). The pellet was thawed and lysed in PMSF lysis
buﬀer (5 mM EDTA, 2 mM EGTA, 0.4 mM PMSF in PBS)
containing protease inhibitor cocktail (Sigma) by three freeze
thaw cycles. TFA (10 μL) was added to precipitate proteins and
the lysate centrifuged (8000 rpm, 30 min, 4 °C). The
supernatant was passed through a 10 kDa cut oﬀ ﬁlter and
the ﬂow through collected and analyzed by reverse phase
HPLC on a Waters HPLC system equipped with a Waters
Atlantis T3, Amide capped C18 5 μm, 6 × 100 mm column.
Samples were manually injected into a Waters ﬂex inject system
into the HPLC system containing a Waters 1525 binary pump.
One-minute fractions were collected in the 5 min window
around the elution time of the synthetic peptide and analyzed
by LC−MS.
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HRE Luciferase Reporter Assay. T-REx-P1, T-REx-
Scramble, or T-REx-HRE cells were transiently transfected
with a HIF dependent ﬁreﬂy luciferase reporter construct
(pGL2-TK-HRE) or a HIF independent ﬁreﬂy luciferase
reporter construct (pGL3-SV40) as a control. Transfected
cells were incubated in the presence or absence of 1 μg/mL
dox. After 24 h, cells were recovered and plated at 25 000 cells/
well in 96 well plates and incubated for 5 h before either
hypoxic or aerobic incubation for 16 h. Fireﬂy luciferase activity
was determined using Bright-Glo Reagent (Promega) according
to the manufacture’s instructions. Luciferase signal was
normalized using the corresponding no-transfection controls
for each plate.
Duolink Proximity Ligation Assay. Duolink proximity
ligation assay (PLA) was conducted using the in situ PLA Kit
(O-Link Bioscience, Uppsala, Sweden) according to the
manufacturer’s instructions. The antibodies used were rabbit
monoclonal anti-HIF-1α (NB100−449, Novus Biologicals) and
mouse monoclonal anti-HIF-1β (H00000405- B01P, Abnova).
Cells were treated with 1 μg/mL dox in normoxia or hypoxia
for 24 after which they were ﬁxed with 2% formaldehyde in
PBS for 10 min and permeabilized with 0.5% Triton (diluted in
PBS) for 10 min. After preincubation with the Duolink
Blocking Reagent for 1 h, samples were incubated overnight
with the primary antibodies to HIF-1α (1:500) and HIF-1β
(1:500). Duolink PLA probes and reagents were added as
recommended by the manufacture’s instructions. Cells were
imaged with a ﬂuorescent microscope (Zeiss Axio Vert.A1).
HIF-2α Knockdown. T-REx-HRE cells were seeded at
20 000 cells/well on 6-well plates and incubated for 24 h such
that cell density reached 50−70% conﬂuence just prior to
transfection with siRNA. Cells were transfected with siRNA
using Lipofectamine RNAiMAX transfection reagent (Life
Technologies) according to the manufacturer’s instructions for
“forward transfection”. Brieﬂy, cell culture media was removed
from cells and replaced with serum-free OptiMEM cell culture
medium (Life Technologies). siRNA and Lipofectamine were
separately, diluted in a volume of OptiMEM equivalent to 10%
of the ﬁnal volume of cells, and incubated at RT for 5 min. The
diluted oligonucleotides and transfection reagent were then
combined, mixed gently, and incubated at RT for 10 min. The
siRNA-Lipofectamine complexes were added dropwise to cells
which were then incubated at 37 °C for 24 h. The ﬁnal
concentration of siRNA was 5 nM and the ﬁnal amount of
Lipofectamine was 0.2% v/v for all experiments. Cells were
either transfected with EPAS1 (HIF-2α) siRNA (Silencer
Select predesigned annealed human oligonucleotide duplex,
s4700, Life Technologies), scrambled siRNA (Silencer Select
negative control number 2, Life Technologies) or vehicle alone.
Following transfection, cells were incubated in hypoxic or
aerobic conditions for 24 h in the presence or absence of 1 μg/
mL for 24 h, then harvested for total RNA extraction.
Cell Viability Assays. T-REx-HRE cells were seeded in
triplicate at 5000 cells per well on 96 well plates 24 h prior to
dosing with 1 μg/mL dox in 100 uL fresh DMEM, DMEM
without glucose or DMEM containing 3 mg/mL 2-deoxy-
glucose. MTT-based cell proliferation assays were performed
on untreated cells on the day of treatment or treated cells 24,
48, or 72 h after treatment, as follows: MTT (Sigma) was
prepared in sterile PBS added to cells at a ﬁnal concentration of
1 mM (10% v/v). Cells were then incubated at 37 °C for 4 h
until intracellular punctate purple precipitated were clearly
visible under the microscope. 75 μL of the culture medium was
the removed from each well and 100 μL DMSO added. The
cells were incubated for 10 min in the dark, with agitation to
dissolve the insoluble formazan particles. Absorbance was
measured at 570 nm on a microplate reader (Tecan Inﬁnite
M200 Pro). ApoToxGlo assays (Promega) were performed on
cells 48 or 72 h after treatment with 1 μg/mL dox according to
the manufacturer’s instructions.
Statistical Analysis. Data analysis was performed with
Prism 6 (Graphpad Software). Statistical signiﬁcance was
evaluated with an unpaired t-test for comparison between two
means and analysis of variance followed by Bonferroni method
for multiple comparisons. A value of p < 0.05 was considered to
denote statistical signiﬁcance.
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